<div>
  <ul>
    <li>
      <p>
        Seoul-based workflow AI drug discovery company Standigm has signed a Memorandum of Understanding (MoU) with Merck Korea to accelerate the discovery of novel therapeutics. The terms and financial details of the agreement have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage Merck&rsquo;s AI-powered retrosynthetic design software &ldquo;Synthia&rdquo; to support Standigm&rsquo;s compound synthesis and potentially expedite the drug discovery process even further compared to traditional AI drug discovery approaches. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/standigm-signs-mou-with-merck-korea-for-ai-drug-discovery-research-301557945.html">
      PR Newswire
    </a>
  </p>
</div>


All Updates

Standigm and Merck Korea to collaborate for AI drug discovery research

Standigm partners with DeepMatter to accelerate drug discovery

Standigm secures investments from Pavilion Capital and SK Chemicals